Finally, Phentermine Shows Long-Term Efficacy and Safety
NATIONAL HARBOR, Md. — For the first time, a randomized, placebo-controlled clinical trial has demonstrated long-term efficacy and safety for the old weight-loss medication phentermine . "Phentermine is actually one of the most popular obesity medicines we have, partly because it's very inexpensive," study investigator
NATIONAL HARBOR, Md. — For the first time, a randomized, placebo-controlled clinical trial has demonstrated long-term efficacy and safety for the old weight-loss medication phentermine . "Phentermine is actually one of the most popular obesity medicines we have, partly because it's very inexpensive," study investigator Jamy D.
Ard, MD, professor of epidemiology and prevention at Wake Forest University School of Medicine, Winston-Salem, North Carolina, told Medscape Medical News . "Clinicians and patients find it to be effective at some level," Ard continued, "yet, it's never been properly tested until now." The stimulant phentermine was first approved for weight loss in 1959, prior to today's FDA efficacy and safety requirements.
It is still marketed generically today, and as of 2024 accounted for about half of all obesity medication prescriptions, even in the GLP-1 era. However, use of the drug is hampered by its labeling for short-term use only (typically 3 months), and its classification as a Schedule IV controlled substance by the US Drug Enforcement Administration (DEA), resulting in state limits on prescription quantities and refills.
Now, researchers hope those constraints might change following results from the 2-year LEAP trial, which showed significant weight loss of about 8% at 1 year, without significant cardiometabolic or other safety issues. The findings aren't published yet but were presented here at Obesity Week 2026 by four of the LEAP investigators.
In his introduction at the meeting session, Ard pointed out that the Schedule IV classification was based on phentermine's similar structure to amphetamine , not because of any evidence for safety concerns. In fact, previous animal and human data suggest no addictive potential, he said.
Study Designed to Reflect Real-World Practice The LEAP trial was funded by the US National Heart, Lung, and Blood Institute. Study drug and matching placebo were donated by KVK Tech, and the lifestyle component was donated by Weight Watchers (WW). The six study sites were located at Wake Forest University (two sites), the University of Texas Health Science Center, HealthPartners Institute in Minnesota, and Kaiser Permanente Southern California (two sites).
A total of 870 participants with BMI 27-44.9and without hypertension were randomized to either 8 mg phentermine (n = 435), orally titrated up to three times daily (24 mg/d), or to placebo (n = 435). Due to DEA scheduling, participants had to return in person monthly to pick up the study drug, although that was later extended to 3 months in Minnesota and Texas.
All participants were provided with lifestyle-based therapy, including a 2-year membership to WW online, a digital scale for self-weighing, and clinician monitoring and advice at baseline, monthly for the first 3 months, then quarterly. "The goal was to simulate a guideline concordant yet real-world translatable intervention that could be replicated in primary care practices with varying levels of resources and training," said study investigator Nicholas M.
Pajewski, PhD, professor of biostatistics and data science at Wake Forest. At week 104, 368 phentermine and 344 placebo group participants remained in the trial. In the intention-to-treat analysis, weight loss at week 26 was 8.4% with phentermine vs 4.5% with placebo, a significant difference ( P < .001).
And by week 52, the weight loss persisted at 8.2% vs 4.6%, P < .001. In addition, more than a third of the phentermine group had a weight loss of 10% or greater at 1 year, reported study investigator Kristina H. Lewis, MD, MPH, associate professor of epidemiology and prevention at Wake Forest.
By 2 years, the phentermine group had gained some weight back, with a total loss of 6.2% from baseline, while the placebo group maintained a 4.7% loss; the difference between the groups remained significant ( P = .003). More than half of the phentermine group maintained a weight loss of 5% or greater at 2 years, Lewis added.
No Major Safety Concerns Seen Systolic blood pressure didn't differ between the groups at any timepoint in the trial. Diastolic blood pressure was significantly higher in the phentermine group at 26 weeks (79.4 vs 77.7 mm Hg, P = .001) and at week 52 (79.5 vs 78.3 mm Hg, P = .03), but not at 2 years (78.9 vs 78.1, P = .17).
Both groups generally maintained tightly controlled blood pressure, said Lewis. Resting heart rate was also significantly higher with phentermine, with 75.4 vs 72.3 beats/min at 2 years ( P < .001), she reported. "Consistent with the mechanism of action of this drug, we did see a slight increase in resting heart rate prevention relative to placebo at all time points, ranging from about three to just under six beats per minute.
But again, if you look at the absolute numbers in terms of heart rate, everybody stayed generally between 70 and 50 beats per minute on average throughout the trial," she noted. No differences were seen in resting metabolic rate at 6 or 24 months, despite the greater weight loss with phentermine, she added.
Adverse events reported more often with phentermine included constipation (42% vs 26%), dry mouth (47% vs 19%), and insomnia (30% vs 14%). "The vast majority of these were reported in the first month of treatment, such that after month three, less than 5% of participants in either group were reporting any of these symptoms," Lewis said.
There was no difference in reported serious adverse events (4.1% vs 4.6%) or discontinuation of study drug due to adverse events (4% in both groups). There were no deaths. There were some differences in cardiovascular parameters, including an elevated blood pressure at a LEAP study visit (6.2% with phentermine vs 5.3% placebo), tachycardia (> 100 beats/min) at a LEAP study visit (2.1% vs 0.2%), and palpitations (8.3% vs 4.6%).
Fewer in the phentermine group reported a new diagnosis of essential hypertension, 1.1% vs 3.2% in the placebo group. The trial wasn't powered to detect differences in major adverse cardiovascular outcomes, but they were rare (0.2% phentermine vs 0.5% placebo), as this was a low-risk population, Lewis pointed out.
Drug dependence, another lingering concern with phentermine, wasn't greater than with placebo. At week 104, a Severity of Dependence Scale score of 3 or greater was seen in 6.3% with phentermine vs 4.3% of the placebo group ( P = .31). Further outcomes will be analyzed and reported in the future, including laboratory results, ECG findings, heterogeneity in blood pressure and weight loss, and quality of life, Lewis said.
Change to FDA Labeling and DEA Scheduling? "We hope [the LEAP results] will help expand people's understanding of what the drug can do in terms of its overall effectiveness and safety," Ard told Medscape . "Many clinicians have a negative perception of phentermine and think it's something that people either shouldn't take at all, or they should only take short term.
That was why it was important for us to study it long term." The push to change the FDA labeling and the DEA scheduling won't come from industry but, he said, it could come from "a coalition of people who represent patients and advocacy for patients, because this is about health equity and access to care." A Good Alternative Asked to comment, session moderator Edmond Wickham, MD, MPH, chief of the Division of Endocrinology, Diabetes and Metabolism at Virginia Commonwealth University, Richmond, said, "I think these findings answer an important question, which is: Can longer-term phentermine treatment be helpful as part of a comprehensive treatment for obesity?" The trial provides more information about the safety of the medication, he added.
"I do really think this is important in supporting our clinical practice in using this medicine long term to help care for our patients with obesity." Obesity expert Amy Rothberg, MD, professor of medicine at the University of Michigan, Ann Arbor, who was not involved in the study, noted that the researchers had done a "phenomenal" job.
"To keep people in a clinical trial for 2 years is exceedingly hard, no matter what the therapy," she told Medscape Medical News. "This is really exciting," said Rothberg. "It was a great trial that tells us for those who cannot access the more expensive GLP-1 therapies, phentermine is a really good alternative." Ard reports research support from Amgen, Eli Lilly, Boehringer Ingelheim, Roche, Regeneron, and Viking Therapeutics; and consulting fees from Eli Lilly, Novo Nordisk, Regeneron, Amgen, Boehringer Ingelheim, Kailera, Currax Pharmaceuticals, Pfizer, Roche, Viking Therapeutics, Nestlé Healthcare Nutrition, and Zealand.
Pajewski has publicly traded stock in Opus Genetics. Lewis is an advisor to Novo Nordisk and a speaker for AstraZeneca. Wickham receives research funding from Novo Nordisk and Eli Lilly.
Rothberg reports grant funding from Abbott, Fractyl, and Boehringer Ingelheim, consulting fees from Boehringer Ingelheim, honoraria from CME Outfitters, expert testimony payment from DLA Piper, and leadership as well as travel and meeting support from the Endocrine Society and the American Board of Obesity Medicine Board of Directors.
Article text via FreeNewsAPI. Rights remain with Medscape.
Read on publisher site → Opens Medscape in a new tab